课题基金 / 基金详情

ALPHA-1-ANTITRYPSIN GENE AND PULMONARY EMPHYSEMA

ALPHA-1-ANTITRYPSIN GENE AND PULMONARY EMPHYSEMA
ALPHA-1-抗胰蛋白酶基因与肺气肿
批准号:
3339193
负责人:
Savio L Woo
金额:
$13.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1982
资助国家:
美国
项目状态:
已结题
起止时间:
1982-09-01 至 1990-03-31

项目摘要

项目成果

Savio L Woo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Alpha-1-antitrypsin is a plasma protease inhibitor that accounts for 90% of the total anti-protease activities in the blood. Reduced serum levels of this protein in certain individuals constitute a genetic disorder known as alpha-1-antitrypsin deficiency, which predisposes affected individuals to high risk of developing chronic obstructive pulmonary emphysema. The deficiency is characterized by the presence of variant alpha-1-antitrypsin of the Z or S phenotypes instead of the normal M phenotype, and is inherited by an autosomal recessive trait. Serum levels of alpha-1-antitrypsin in ZZ homozygotes and SZ heterozygotes are 12 and 35% of the normal individuals, respectively. The frequencies of the Z and S genes are such that 1/3000 to 1/4000 of caucasians in the United States are of the ZZ phenotype and 1/800 are of the SZ phenotype. It has been estimated that 80-90% of ZZ homozygotes will develop pulmonary emphysema of various severity, and there is no cure for this genetic disorder at the present time. Subtle amino acid substitutions in alpha-1-antitrypsin between the Z and S deficient phenotypes and the normal M phenotype have been reported. Since only limited amino acid sequence of the normal and variant proteins have been determined, whether there are additional amino acid substitutions between these proteins are not known at the present time. Using Recombinant DNA Technology, we propose to isolate and characterize the human Alpha-1-antitrypsin gene from normal and deficient individuals by molecular cloning. Comparison of the structural organization and nucleotide sequence between the cloned genes should reveal any additional amino acid substitutions in the variant proteins and would thereby establish the molecular basis of the deficiency at the gene level. This information will then permit the development of a simple and reliable method for prenatal diagnosis of the genetic disorder by gene mapping. Early detection of individuals with the genetic disorder will permit better management of the deficiency, which will in turn reduce the risk of their developing pulmonary emphysema later in life. Finally, attempts will be made to better understand the cause(s) of the deficiency by examining the expression of the deficient genes after their introduction through DNA mediated gene transfer into a human hepatoma cell line which synthesizes and secretes normal Alpha-1-antitrypsin.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/s0021-9258(18)68646-6
发表时间: 1988-05
期刊: The Journal of biological chemistry
影响因子: --
作者: [R. Sifers;S. Brashears-Macatee;Vincent J. Kidd;H. Muensch;Savio L. C. Woo]
通讯作者: R. Sifers;S. Brashears-Macatee;Vincent J. Kidd;H. Muensch;Savio L. C. Woo
Complete cDNA sequence and chromosomal localization of mouse alpha 1-antitrypsin.
小鼠 α1-抗胰蛋白酶的完整 cDNA 序列和染色体定位。
DOI: 10.1016/0888-7543(90)90453-2
发表时间: 1990
期刊: Genomics
影响因子: 4.4
作者: [Sifers,RN, Ledley,FD, Reed-Fourquet,L, Ledbetter,DH, Ledbetter,SA, Woo,SL]
通讯作者: Woo,SL
Molecular evolution of serpins: homologous structure of the human alpha 1-antichymotrypsin and alpha 1-antitrypsin genes.
丝氨酸蛋白酶抑制剂的分子进化:人类α1-抗胰蛋白酶和α1-抗胰蛋白酶基因的同源结构。
DOI: 10.1021/bi00398a033
发表时间: 1987
期刊: Biochemistry
影响因子: 2.9
作者: [Bao,JJ, Sifers,RN, Kidd,VJ, Ledley,FD, Woo,SL]
通讯作者: Woo,SL
Retroviral mediated transfer and expression of human alpha 1-antitrypsin in cultured cells.
逆转录病毒介导的人α1-抗胰蛋白酶在培养细胞中的转移和表达。
DOI: 10.1016/0378-1119(87)90370-2
发表时间: 1987
期刊: Gene
影响因子: 3.5
作者: [Ledley,FD, Grenett,HE, Bartos,DP, Woo,SL]
通讯作者: Woo,SL
10
    Anaerobic Bacteria as Oncopathic Agents for Pancreatic Cancer
    Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
    Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
    Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
    海外基金